$2.15
-0.11 (-4.87%)
Open$2.23
Previous Close$2.26
Day High$2.24
Day Low$2.09
52W High$80.36
52W Low$2.09
Volume—
Avg Volume33.5K
Market Cap3.11M
P/E Ratio—
EPS$-91.65
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
+1,732.1% upside
Current
$2.15
$2.15
Target
$39.39
$39.39
$26.66
$39.39 avg
$54.88
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.03M | 1.06M | 807.5K |
| Net Income | -278,352 | -347,095 | -248,556 |
| Profit Margin | -27.1% | -32.7% | -30.8% |
| EBITDA | -433,012 | -468,823 | -342,942 |
| Free Cash Flow | -135,403 | -181,532 | -119,491 |
| Rev Growth | +14.1% | -2.0% | +8.2% |
| Debt/Equity | 0.22 | 0.23 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |